Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation

Digestive and Liver Disease

Volumn 46, Issue 11, 2014, Pages 1014-1019

  Facciorusso, Antonio ^a   Del Prete, Valentina ^a   Antonino, Matteo ^a   Crucinio, Nicola ^a   Neve, Viviana ^a   Di Leo, Alfredo ^b   Carr, Brian I ^c   Barone, Michele ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

HCC; Liver cancer; PRS; RFA

Indexed keywords

CHLOROTRIANISENE; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHILD PUGH SCORE; FEMALE; FEVER; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908241374     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.012     Document Type: Article

References (20)

1. El-Serag H.B. Hepatocellular carcinoma. New England Journal of Medicine 2011, 365:1118-1127.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012, 56:908-943.
3. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology 2008, 48(Suppl. 1):S20-S37.
4. Lencioni R., Cioni D., Crocetti L., et al. Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005, 234:961-967.
5. Omata M., Tateishi R., Yoshida H., et al. Treatment of hepatocellular carcinoma by percutaneous tumour ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004, 127:S159-S166.
6. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47:82-89.
7. Pompili M., Saviano A., de Matthaeis N., et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey. Journal of Hepatology 2013, 59:89-97.
8. Reig M., Rimola J., Torres F., et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013, 58:2023-2031.
9. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
10. Mazzaferro V., Sposito C., Bhoori S., et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013, 57:1826-1837.
11. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Disease 2010, 30:52-60.
12. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009. NIH Publication # 09-7473.
13. Zietemann V.D., Schuster T., Duell T.H. Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. Journal of Thoracic Disease 2011, 3:88-98.
14. Hung J.J., Hsu W.H., Hsieh C.C., et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009, 64:192-196.
15. Song I.H1, Yeom S.W., Heo S., et al. Prognostic factors for post-recurrence survival in patients with completely resected stage I non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery 2014, 45:262-267.
16. Hsu P.K., Wang B.Y., Huang C.S., et al. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. Journal of Gastrointestinal Surgery 2011, 15:558-565.
17. Mitra A.P., Quinn D.I., Dorff T.B., et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU International 2012, 109:846-854.
18. Kim J.M., Kang T.W., Kwon C.H., et al. Single hepatocellular carcinoma ≤3cm in left lateral segment: liver resection or radiofrequency ablation?. World Journal of Gastroenterology 2014, 20:4059-4065.
19. N'Kontchou G., Mahamoudi A., Aout M., et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009, 50:1475-1483.
20. Oxnard G.R., Morris M.J., Hodi F.S., et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. Journal of the National Cancer Institute 2012, 104:1534-1541.